User profiles for J.Y. Chen
Judy Y.-C. ChenPh. D., Chemistry, Columbia University Verified email at columbia.edu Cited by 11349 |
Plasma-surface modification of biomaterials
PK Chu, JY Chen, LP Wang, N Huang - Materials Science and Engineering …, 2002 - Elsevier
Plasma-surface modification (PSM) is an effective and economical surface treatment
technique for many materials and of growing interests in biomedical engineering. This article …
technique for many materials and of growing interests in biomedical engineering. This article …
Nest-like silicon nanospheres for high-capacity lithium storage
Nest-like Si nanospheres and their highly reversible lithium storage (3952 mAh g{sup -1} at
100 mA g{sup -1}) and excellent high-rate capability (3052 mAh g{sup -1} at 2000 mA g{sup -…
100 mA g{sup -1}) and excellent high-rate capability (3052 mAh g{sup -1} at 2000 mA g{sup -…
Systematic measurements of identified particle spectra in , , and collisions at the STAR detector
…, S Chattopadhyay, HF Chen, JH Chen, JY Chen… - Physical Review C, 2009 - APS
Identified charged-particle spectra of π±, K±, p, and p at midrapidity (| y|< 0. 1) measured by
the dE/dx method in the STAR (solenoidal tracker at the BNL Relativistic Heavy Ion Collider) …
the dE/dx method in the STAR (solenoidal tracker at the BNL Relativistic Heavy Ion Collider) …
Photophysical and photochemical studies of zinc (II) phthalocyanine derivatives—effects of substituents and solvents
A Ogunsipe, JY Chen, T Nyokong - New Journal of Chemistry, 2004 - pubs.rsc.org
The effects of substituents and solvents on the photophysical and photochemical parameters
of zinc(II) phthalocyanines are reported. The complexes studied are zinc phthalocyanine (…
of zinc(II) phthalocyanines are reported. The complexes studied are zinc phthalocyanine (…
Precambrian sponges with cellular structures
CW Li, JY Chen, TE Hua - Science, 1998 - science.org
Sponge remains have been identified in the Early Vendian Doushantuo phosphate deposit
in central Guizhou (South China), which has an age of ∼580 million years ago. Their …
in central Guizhou (South China), which has an age of ∼580 million years ago. Their …
Survey of stress reactions among health care workers involved with the SARS outbreak
YM Bai, CC Lin, CY Lin, JY Chen… - Psychiatric …, 2004 - Am Psychiatric Assoc
… Jen-Yeu Chen, MD , … Jen-Yeu Chen … Chen, and Dr. Chue are affiliated with the Yu-Li
Veterans Hospital, 91, Hsin Hsing Street, Yu-Li, Hua-Lien, 981, Taiwan (e-mail, [email protected]). Dr…
Veterans Hospital, 91, Hsin Hsing Street, Yu-Li, Hua-Lien, 981, Taiwan (e-mail, [email protected]). Dr…
[HTML][HTML] Serologic markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in Taiwanese men
YC Chien, JY Chen, MY Liu, HI Yang… - … England Journal of …, 2001 - Mass Medical Soc
Background It is probable but unproven that Epstein–Barr virus (EBV) has a role in nasopharyngeal
carcinoma. We determined whether antibodies against EBV are present before the …
carcinoma. We determined whether antibodies against EBV are present before the …
Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently
…, H Nakshatri, M Saunders, T Zacharewski, JY Chen… - Cell, 1992 - cell.com
We have purified and cloned a HeLa cell nuclear protein that strongly stimulates binding of
retinoic acid and thyroid hormone receptors (RARs and TRs) to response elements. The …
retinoic acid and thyroid hormone receptors (RARs and TRs) to response elements. The …
[HTML][HTML] The gut microbiome in atherosclerotic cardiovascular disease
The gut microbiota has been linked to cardiovascular diseases. However, the composition
and functional capacity of the gut microbiome in relation to cardiovascular diseases have not …
and functional capacity of the gut microbiome in relation to cardiovascular diseases have not …
[HTML][HTML] CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma
…, GP Collins, T Tran, J Lynn, JY Chen… - … England Journal of …, 2018 - Mass Medical Soc
Background The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint
inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab …
inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab …